• September 2009
    • Sigmapharm successfully completes an FDA inspection focused on its current GMP status and a Pre-Approval-Inspection related to its ANDA No. 091004.

    • Sigmapharm files an Abbreviated New Drug Application (ANDA No. 200295).

  • July 2009

    Sigmapharm files an Abbreviated New Drug Application (ANDA No. 091619).

  • April 2009

    Sigmapharm launches, through Rising Pharmaceuticals, Inc., its 1st generic product, Amiloride Hydrochloride Tablets, USP 5 mg, which is the second approved generic equivalent to MIDAMOR® Tablets.

  • January 2009

    Sigmapharm receives FDA approval for generic Amiloride Hydrochloride Tablets, USP 5 mg, based on its ANDA No. 079133.  This is our 1st ANDA approval.

  • November 2008

    Sigmapharm files an Abbreviated New Drug Application (ANDA No. 091004).

  • March 2008

    Sigmapharm files an Abbreviated New Drug Application (ANDA No. 090462).

  • January 2008

    Sigmapharm completes its 1st FDA inspection focused on its current GMP status and a Pre-Approval-Inspection related to its ANDA No. 079133.

  • July 2007

    Sigmapharm files its 1stAbbreviated New Drug Application (ANDA No. 079133).

  • September 2006

    Sigmapharm fully relocates to a new 60,000 sq. ft. facility located in Bensalem, Pennsylvania.  Our new address is 3375 Progress Drive, Bensalem, PA 19020.  Our new phone and fax numbers are (215) 352-6655 and (215) 352-6644, respectively.

  • May 2005

    Sigmapharm moves to a 5,000 sq. ft. facility located at the Oxford Valley Mall in Langhorne, Pennsylvania.